Efficacy and Safety of Emapalumab and Anakinra in Reducing Hyperinflammation and Respiratory Distress in Patients With COVID-19 Infection.

NCT04324021 · clinicaltrials.gov ↗
PHASE2,PHASE3
Phase
TERMINATED
Status
16
Enrollment
INDUSTRY
Sponsor class

Stopped Standard of care evolved during the timeframe of the study and had critical impact on recruitment. Early termination was not based on safety reasons but due to the reasons mentoined above. The ongoing patients were completed.

Conditions

Interventions

Sponsor

Swedish Orphan Biovitrum